Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Brexit
Brexit talks threaten supply of medical technologies
As concern grows that the outcome could undermine the regulatory framework...
the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....

Infographics